{"name":"Akamis Bio","slug":"akamis-bio","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Capecitabine oral administration","genericName":"Capecitabine oral administration","slug":"capecitabine-oral-administration","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Capecitabine oral administration","genericName":"Capecitabine oral administration","slug":"capecitabine-oral-administration","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxOZ184MUFzVGhQV3FZbmQ3OC1MMFduRnl5Y3Z5NXZSNzR3d1pGc0NKNzBvTGk1UndRRVJrZU5JVTRTbHRXX203YW04NW5jRXFJTU9DNmh1NEo4aWM2djZnQ3o3NHV5UTNUTmVNTjN5SkpNMk9lZjBaV05hdHJDU2hkQ09WUWdQZ0YxN25XVWVLRlJxWno0bXVEbEw3bXhQbEVDYjY4VUxwSFpXSldtNzg1NnU5VEFkYzdXVzZxaDhZTmpYbXR5TzJNSkVfZ29jNkN4ZUtfeUQ2TnBaeHUtTEZpTHR6OEQ4d3RlT3lXVFJ2aVk1amgtUkNjZUdqbEpvLTh1eWZxZnV0aEk5NER6SUxZM2pLU1UycWMxMDhBMmJzb1ItUTFtODdhcndfZGRBUXVQVU5V?oc=5","date":"2026-03-17","type":"trial","source":"Business Wire","summary":"Akamis Bio to Present Initial Data from the Phase 1b FORTRESS Study of NG-350A in Mismatch Repair-Proficient Locally Advanced Rectal Cancer at AACR 2026 - Business Wire","headline":"Akamis Bio to Present Initial Data from the Phase 1b FORTRESS Study of NG-350A in Mismatch Repair-Proficient Locally Adv","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxOQTR0d1l3a3B2VmdFdjY0QkJVZ01rYmtPV0gtNERtMXMyN1lXdTdpOTFRRjFjREFaSENvbDByU2JUdzRVZ2Mxc3dsbU8zYm5MUElhVGl3RHkyU3NzaTZ5b3U2T1NOUGlUaE90MDNtUTB1Z2xIeWRSZ1NfTEpwU1hzcDZiZnpYX0puU1lTZmYyMDZ6YS02YnowdU1jbU1wZmh0d3pYNmpiYV9VVnpzTXRva09wdE9RUzZ1d3dWOGtVMGJwVmFaVkJndlJMM09oSWRhUWZKVUJJSW1iSXBWc0p5bm83ZlZOYmxaZXdEOG1ZZHZib2pxcUltWmFrdjJha0JhRFNKYTF3QlFjd0hEN29VTVJB?oc=5","date":"2026-02-04","type":"trial","source":"PR Newswire","summary":"Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - PR Newswire","headline":"Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPLXB0T0FLVWJYdEQ3V0xmTldPS0c0SlR6WktSaGI2Y0pSUWJ6UUF1aVh0UDBhNXVxU0pJZjc2ZUFJckh0cEFRd0lveTh0RWJoNGNVLVRXZkNjc09fRHNfSEFoTGN6VnhhYjVhdk1Oa1NGcldoM1hwWjdPajlFaFJEU0dOd3JuYXh2azNuQmFrM0x3UUROU2wzZW5JY2tock9RNERSMzljbnZKMERPc0dWX2RHdXdDajBOd2dwUUpQUmxaSTVxclc2ZmNEbWVoVHBFVWplalU4V3d0YnZpUEhna2lmVEs2bDVkNl85Nmc2dkszLVV3VHJTQ2RVVTFUdGp5SFJRcFVLWlM?oc=5","date":"2025-10-15","type":"regulatory","source":"BioSpace","summary":"Akamis Bio Receives FDA Fast Track Designation for NG-350A for the Treatment of Mismatch Repair-Proficient Locally Advanced Rectal Cancer - BioSpace","headline":"Akamis Bio Receives FDA Fast Track Designation for NG-350A for the Treatment of Mismatch Repair-Proficient Locally Advan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOYlNDazd5QWFrVVk2NnkzVk1Zb1h0M0IzdzJUa0x2REtwZWRHd051elNlckU0cWZuYWxGd0RxSmIyUEpTeERobjVOOXNuYTY1VTdDWkx2NkIxQjlvT05UaFpSYnlObkF0SjcwX2hKMjJxaEJEZG15U1FILV8tTzQwVlFPbk5yWTRNQ2ZBcjJn?oc=5","date":"2025-08-12","type":"pipeline","source":"Yahoo Finance","summary":"Akamis Bio Announces the Appointment of Andrew Hirsch to the Company’s Board of Directors - Yahoo Finance","headline":"Akamis Bio Announces the Appointment of Andrew Hirsch to the Company’s Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAJBVV95cUxNYUIxR3h4N3FDTzFNbGpGZ0IwTzdHS2x0czJPNlNsXzZKeEhzNGRJZEtIN3F3NVAtYWV6d2xqNEpncF9nbTNSRUJhWmNXdy0wbWU5NlZtcW5wYklBZEVVYW1CdnhlUU5OMl9lUVhVYkdjMHRjeEZFZ2dyNWV5bi13WlFXTFhhMFpSZkxBN0hKOVoxWEVCejkzcHdndFdTSWJoQ2t1d1RUdVZuZ3lFUEhzRi11b1JhQWtibDhQb3Nta0JBb1dqWFpLYlpYcl9Ua2xDZHVITVg5RE9SbWlxY3RrNWZJdkRlcF8xNXlPWEdjQkU2NUhYbHNoWlBybGcxLTVPMmEwcA?oc=5","date":"2025-04-03","type":"trial","source":"BioSpace","summary":"Akamis Bio Announces Enrollment of First Patient in Phase 1b FORTRESS Trial of NG-350A in Patients with Locally Advanced Rectal Cancer - BioSpace","headline":"Akamis Bio Announces Enrollment of First Patient in Phase 1b FORTRESS Trial of NG-350A in Patients with Locally Advanced","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxONVhONnlUeTUxUTNDMWdZdnBrZ1c2U2owNGlMdzBBdzNCM010WFhjQ1JZZHZlb1NPWFhGQTRtWEpFYkpDcmt2NGhWdTNieWkyaUx2cm1wVl9XY2xES0hNTVZDSkllWXZYelVxQUtrd0NaUVRQMU01NS1LV2RWQnVicTVwSDNhMllvMTZpNnRZRGtNNEJMV1ZwVnZUNGxVLU94Z1B2UnhKdW5hQnNtLWNaZkhyU0p6di1DdEI4ejVCUDFtcWRYWmpZZ1FQbmxVVTZaQkQwVw?oc=5","date":"2024-12-18","type":"deal","source":"Genetic Engineering and Biotechnology News","summary":"Akamis Bio Raises $60 Million for Cancer Gene Therapy, Signs Licensing Deal with Xuanzhu Biopharma - Genetic Engineering and Biotechnology News","headline":"Akamis Bio Raises $60 Million for Cancer Gene Therapy, Signs Licensing Deal with Xuanzhu Biopharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNQ0xNUkNjZmNwYUlFa2M1TE0zX3ZBN0pSRzhaNUZQVjRac2xiSHp3Z1c1NklBVFdWZUUwcU5NbEhkSkhNYi1MSGJERE10UjdnY3llNThMU2QtZkhMemlRWjY4a3lNQldCR0tKWmpYejVIWE1hYjVZbkVYc182VVNTVkxzMktXTk1IbUlfeGpuRTZfVjR4S2hIanhXdnhtdGcxQkNlWE9zZU0yN2trMm1VejNUYkdmaF9KQ0E?oc=5","date":"2023-07-06","type":"pipeline","source":"Fierce Pharma","summary":"CXL Ophthalmics taps into its tech as it ditches old name to become Epion Therapeutics - Fierce Pharma","headline":"CXL Ophthalmics taps into its tech as it ditches old name to become Epion Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQYXEwS1d5U2lEdEFZY2hRN2pSSzZnYUp3OTRjMmk2cUYybHJZTFFBb2ZDb2VPbHdta2k3YnU1NHE2eVJndmxVQVNnRmZZTTU4RV9aMFprd2hhbnFEN0IxaWtJdFppRUZYYkZpbHNxQS1RdHFTM3JJelpiRUlzaS14NEtrdHJ6cTR5M0EyVGxTcjYxbWlYVzhBYTh3SFhIa1Z6Ym9ERnlZZUp3WFNXaEZndDExQlJ4NXpWMzJDTmJESQ?oc=5","date":"2023-01-06","type":"pipeline","source":"Fierce Pharma","summary":"PsiOxus Therapeutics is no more as cancer biotech taps Greek mythology to rebrand as Akamis Bio - Fierce Pharma","headline":"PsiOxus Therapeutics is no more as cancer biotech taps Greek mythology to rebrand as Akamis Bio","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}